leucinerich
lrg
serum
glycoprotein
unknown
function
shown
promis
base
qualit
assess
biomark
certain
diseas
includ
microbi
infect
cancer
howev
lack
quantit
assay
lrg
limit
applic
indirect
enzymelink
immunosorb
assay
elisa
quantifi
lrg
human
serum
describ
cytochrom
c
employ
captur
ligand
monoclon
antibodi
specif
lrg
use
detect
captur
glycoprotein
applic
assay
quantifi
lrg
variou
patient
sera
demonstr
concentr
lrg
sera
control
subject
determin
assay
approxim
consist
expect
publish
report
lrg
found
significantli
elev
sera
patient
bacteri
infect
toxic
shock
syndrom
tss
lrg
slightli
elev
patient
infect
human
immunodefici
viru
compar
uninfect
control
subject
normal
level
lrg
observ
patient
noninfecti
diseas
inflammatori
arthriti
neurolog
disord
primarili
parkinson
diseas
although
lrg
creactiv
protein
crp
produc
liver
classifi
acutephas
protein
signific
correl
level
lrg
crp
sera
patient
thu
lrg
crp
measur
nonredund
indic
differ
physiolog
context
elisa
describ
report
use
assess
serum
lrg
biomark
clinic
diagnost
evalu
serum
compon
one
least
invas
approach
clinic
diagnosi
prognosi
consider
potenti
exploit
approach
even
present
inde
impact
number
serum
protein
diseas
diagnosi
prognosi
fulli
known
limit
larg
part
avail
rapid
quantit
assay
case
point
serum
glycoprotein
lrg
lrg
first
purifi
human
serum
haupt
baudner
amino
acid
sequenc
determin
year
later
takahashi
et
al
glycoprotein
molecular
weight
approxim
kda
contain
carbohydr
weight
haupt
baudner
compris
repetit
sequenc
leucinerich
motif
leucin
residu
make
amino
acid
composit
takahashi
et
al
base
mrna
analysi
lrg
predict
express
liver
cell
ncbi
gd
gd
gd
neutrophil
odonnel
et
al
upregul
mous
model
inflamm
norkina
et
al
function
lrg
known
although
shown
bind
cytochrom
c
cyt
c
cum
et
al
hypothes
play
role
cell
surviv
thompson
et
al
increas
serum
level
glycoprotein
qualit
demonstr
sever
group
patient
proteom
approach
involv
twodimension
gel
electrophoresi
lrg
consist
elev
qualit
assess
sera
patient
bacteri
infect
includ
haemophili
influenza
type
b
salmonella
streptococcu
pyogen
often
alway
increas
viral
infect
includ
varicellazost
measl
mump
bini
et
lrg
also
overexpress
along
acutephas
protein
patient
sever
acut
respiratori
syndrom
sar
chen
et
al
addit
increas
serum
lrg
observ
patient
sever
type
cancer
includ
pancreat
kakisaka
et
al
liver
kawakami
et
al
lung
cancer
okano
et
al
twodimension
gel
electrophoresi
conjunct
mass
spectrometri
valid
western
blot
evalu
lrg
serum
biomark
would
enhanc
develop
quantit
assay
measur
glycoprotein
end
prepar
mous
monoclon
antibodi
mab
reactiv
human
lrg
use
conjunct
cyt
c
captur
ligand
develop
indirect
enzymelink
immunosorb
assay
elisa
quantifi
lrg
employ
assay
examin
serum
level
lrg
patient
varieti
disord
includ
inflammatori
arthriti
neurolog
disord
includ
parkinson
diseas
pd
toxic
shock
syndrom
tss
result
infect
staphylococc
aureu
bacteria
infect
human
immunodefici
viru
hiv
creactiv
protein
crp
promin
acutephas
protein
also
quantifi
compar
lrg
determin
two
biomark
redund
provid
differ
clinic
inform
lrg
pool
human
sera
obtain
sever
volunt
donor
approv
univers
minnesota
institut
review
board
purifi
previous
describ
slight
modif
cum
et
al
adsorpt
deaesephacel
ml
sigmaaldrich
chem
co
st
loui
mo
supern
ammonium
sulfat
precipit
serum
dialyz
mm
sodium
phosphat
ph
stepwis
twofold
increas
sodium
chlorid
concentr
begin
mm
result
elut
human
lrg
mm
sodium
chlorid
eluat
contain
lrg
adsorb
ml
hors
cyt
caffigel
biorad
laboratori
richmond
ca
wash
phosphatebuff
salin
ph
pb
ml
elut
stepwis
ml
acet
acid
follow
acet
acid
acet
acid
eluat
contain
approxim
lrg
lyophil
dissolv
mm
sodium
phosphat
ph
dialyz
mm
sodium
phosphat
ph
pass
hydroxylapatit
biorad
remov
acid
protein
may
bound
cyt
caffigel
column
due
electrostat
interact
haupt
baudner
protein
puriti
assess
gel
code
blue
stain
sdspage
gel
acrylamid
gradient
pierc
biotechnolog
rockford
il
concentr
lrg
determin
absorb
nm
assum
extinct
coeffici
mm
calcul
amino
acid
composit
gill
von
hippel
individu
blood
sampl
obtain
patient
control
subject
follow
protocol
approv
univers
minnesota
institut
review
board
clot
room
temperatur
blood
sampl
refriger
h
centrifug
rpm
separ
sera
clot
sera
frozen
aliquot
assay
lrg
crp
enhanc
immunogen
human
lrg
coval
coupl
equimolar
amount
hemocyanin
use
glutaraldehyd
jemmerson
balbc
mice
inject
ip
protein
emulsifi
complet
freund
adjuv
challeng
week
later
conjug
protein
emulsifi
incomplet
freund
adjuv
protocol
inject
surgic
procedur
remov
spleen
immun
mice
approv
univers
minnesota
institut
anim
care
use
committe
monoclon
antibodi
specif
human
lrg
mab
determin
express
heavi
light
chain
isotyp
respect
indirect
elisa
obtain
fuse
splenocyt
immun
mous
week
secondari
challeng
myeloma
cell
use
polyethylen
glycol
kearney
et
al
antibodysecret
hybridoma
select
elisa
base
abil
antibodi
produc
bind
human
lrg
captur
serum
cyt
c
assay
plate
select
hybridoma
subclon
limit
dilut
use
normal
mous
splenocyt
feeder
cell
immunoaffin
chromatographi
mab
purifi
coupl
bead
use
immunoaffin
chromatographi
adsorb
lrg
complex
cyt
c
mab
purifi
ascit
fluid
two
step
precipit
satur
ammonium
flow
deaesephacel
bead
mm
sodium
phosphat
ph
mab
mg
coupl
mg
cyanogenbromid
activ
sepharos
sigmaaldrich
chem
co
accord
manufactur
instruct
cyt
c
lrg
incub
molar
ratio
h
continu
mix
complex
adsorb
immunoaffin
column
absorb
nm
nm
protein
elut
acet
acid
follow
wash
immunoaffin
column
ml
pb
molar
ratio
cyt
c
bound
lrg
determin
detect
possibl
protein
bound
lrg
serum
human
serum
dilut
pb
lrg
adsorb
onto
mab
column
similar
protocol
employ
adsorb
serum
protein
bind
cyt
c
employ
hors
cyt
c
coupl
affigel
ms
determin
protein
gel
slice
perform
univers
minnesota
center
mass
spectrometri
proteom
previous
describ
cum
et
al
employ
qstar
xl
quadrupol
malditof
appli
biosystem
inc
foster
citi
ca
malditoftof
malditoftof
analyz
appli
biosystem
inc
biflex
iii
malditof
delay
extract
bruker
dalton
inc
billerica
statist
analysi
perform
protein
pilot
v
softwar
appli
biosystem
inc
sdspage
protein
band
elecrophoret
transfer
hybondecl
nitrocellulos
membran
amersham
bioscienc
piscataway
nj
block
dri
milk
pb
contain
triton
probe
cyt
c
use
mab
liu
et
al
follow
hrpcoupl
goat
antimous
immunoglobulin
pierc
biotechnolog
blot
develop
use
supersign
west
femto
substrat
pierc
biotechnolog
exposur
hyperfilm
ecl
amersham
bioscienc
bind
lrg
cyt
c
assess
employ
indirect
elisa
engval
sinc
bind
lrg
cyt
c
evolutionarili
conserv
thompson
et
al
hors
cyt
c
substitut
human
cyt
c
adsorb
microtit
plate
captur
lrg
protein
dissolv
concentr
pb
ph
adsorb
h
well
maxisorp
plate
nalg
nunc
intern
rochest
ny
plate
wash
twice
pb
contain
triton
dilut
purifi
human
lrg
standard
human
sera
dilut
greater
ad
well
h
two
wash
mous
antihuman
lrg
mab
pb
contain
triton
ad
well
incub
h
plate
wash
twice
incub
dilut
goat
antimous
igg
whole
molecul
conjug
horseradish
peroxidas
sigmaaldrich
chem
co
h
plate
wash
three
time
citratephosph
buffer
ph
contain
substrat
hydrogen
peroxid
color
indic
ophenylenediamin
ad
well
reaction
allow
continu
min
stop
addit
n
sulfur
acid
absorb
nm
determin
employ
titertek
multiskan
plate
reader
flow
laboratori
mcclean
va
serum
sampl
assay
triplic
lrg
concentr
determin
averag
absorb
read
standard
curv
plot
sigmoid
dose
respons
equival
paramet
logist
equat
employ
prism
program
graphpad
softwar
inc
san
diego
ca
statist
signific
also
analyz
employ
prism
program
commerci
kit
employ
quantifi
crp
alerchek
portland
sera
dilut
test
depend
upon
quantiti
crp
indirect
sandwich
elisa
detect
quantifi
human
lrg
prepar
employ
ligand
cyt
c
captur
glycoprotein
mab
specif
human
lrg
detect
sinc
human
lrg
bind
cyt
c
mani
speci
includ
varieti
mammal
bird
fish
cum
et
al
thompson
et
al
hors
cyt
c
employ
captur
human
lrg
assay
describ
typic
curv
purifi
lrg
use
standard
assay
quantifi
lrg
shown
fig
follow
purif
pool
human
sera
lrg
migrat
sdspage
expect
molecular
weight
approxim
kda
fig
typic
standard
curv
elisa
shown
fig
sinc
calcul
concentr
lrg
control
serum
approxim
see
sera
must
dilut
least
effect
quantif
assay
although
cyt
c
detect
normal
serum
report
concentr
ngml
barczyk
et
al
pullerit
et
al
low
theoret
inhibit
cyt
cmediat
captur
lrg
concentr
cyt
c
serum
nevertheless
assess
whether
cyt
c
compon
serum
might
bind
lrg
interfer
quantif
elisa
serum
dilut
pb
pass
ml
column
sepharos
bead
lrgspecif
mab
coval
bound
adsorb
protein
elut
acet
acid
electrophores
sdspage
complex
purifi
lrg
cyt
c
form
vitro
use
purifi
lrg
cyt
c
molar
ratio
effect
adsorb
mabcoupl
bead
fig
experi
molar
ratio
cyt
c
lrg
bound
complex
calcul
base
extinct
coeffici
two
protein
nm
nm
concentr
cyt
c
rel
lrg
incub
solut
increas
fold
molar
ratio
two
compon
complex
approach
result
shown
protein
normal
human
serum
allow
adsorb
mabcoat
bead
lrg
mab
domin
protein
elut
column
determin
coomassi
blue
stain
gel
fig
signific
band
beyond
also
elut
control
mabcoupl
sepharos
bead
observ
particular
cyt
c
migrat
kda
detect
eluat
adsorpt
pool
sera
tss
patient
elev
lrg
see
gave
result
normal
sera
fig
anoth
experi
band
gel
similar
transfer
nitrocellulos
probe
cyt
cspecif
mab
use
sensit
chemiluminesc
reaction
detect
also
observ
cyt
c
adsorb
sera
either
control
subject
tss
patient
although
purifi
cyt
c
detect
fig
lane
experi
conclud
lrg
bound
cyt
c
signific
extent
sera
patient
examin
competit
elisa
increas
amount
solubl
purifi
cyt
c
ad
well
prior
addit
serum
contain
lrg
dilut
inhibit
observ
concentr
solubl
cyt
c
fig
repres
upper
limit
cyt
c
estim
present
normal
human
serum
pullerit
et
al
complet
inhibit
lrg
detect
achiev
approxim
upper
limit
cyt
c
normal
serum
indic
caution
necessari
employ
assay
describ
herein
quantifi
lrg
sera
patient
except
high
level
cyt
c
eg
patient
form
liver
diseas
patient
undergo
cours
cancer
chemotherapi
benari
et
al
barczyk
et
al
addit
show
cyt
c
coimmunoprecipit
lrg
serum
data
fig
c
indic
promin
serum
protein
coimmunoprecipit
lrg
use
mab
confirm
identifi
serum
protein
might
adsorb
cyt
c
elisa
lrg
pass
ml
normal
human
serum
dilut
sera
pool
tss
patient
cyt
caffigel
visual
gel
fig
serum
lrg
complex
cyt
c
protein
signific
extent
assess
sdspage
protein
adsorb
elut
sepharos
bead
antilrg
mab
molecul
coval
attach
complex
purifi
cyt
c
purifi
lrg
readili
adsorb
mab
column
demonstr
effect
approach
defin
molecul
might
complex
lrg
serum
molecul
elut
column
substanti
amount
follow
adsorpt
ml
control
serum
b
ml
serum
pool
tss
patient
c
lrg
mab
cyt
c
observ
western
blot
probe
cyt
c
ng
standard
protein
detect
either
control
sera
sera
pool
tss
patient
adsorb
elut
antilrg
mab
column
code
blue
stain
protein
band
eluat
serum
equival
protein
identifi
mass
spectrometri
shown
fig
addit
band
kda
expect
human
lrg
promin
band
kda
observ
along
lesser
intens
band
molecular
weight
approxim
kda
kda
protein
confirm
lrg
malditof
ms
p
b
msm
two
individu
peptid
yield
mascot
score
kda
protein
identifi
hemopexin
employ
malditof
delay
extract
p
b
malditoftof
uniqu
peptid
hemopexin
observ
confid
kda
protein
identifi
plasmin
employ
malditoftof
twelv
uniqu
peptid
complet
b
ion
defin
confid
includ
peptid
two
amino
acid
remov
carboxyl
terminu
residu
amino
terminusproxim
peptid
residu
although
peptid
observ
also
present
plasminogen
base
size
protein
particular
peptid
observ
extend
residu
conclud
protein
plasmin
plasminogen
plasmin
affin
lysin
robbin
et
al
hors
cyt
c
contain
lysin
residu
plasmin
molecul
serum
like
adsorb
cyt
caffigel
basi
obtain
human
plasmin
commerci
supplier
sigmaaldrich
chem
co
found
employ
elisa
describ
herein
bind
mab
cyt
ccoat
plate
incub
plasmin
observ
data
shown
although
hemopexin
bind
nativ
cyt
c
bind
heme
moieti
expos
chemicallycleav
fragment
molecul
jemmerson
denatur
molecul
cyt
c
expos
heme
like
aros
prewash
cyt
caffigel
column
acet
acid
andor
chemic
coupl
protein
matrix
allow
hemopexin
adsorb
serum
howev
cyanogenbromidecleav
fragment
hors
cyt
c
known
bind
hemopexin
jemmerson
substitut
nativ
protein
elisa
bind
mab
observ
indic
hemopexin
may
bound
denatur
cyt
c
assay
detect
use
mab
result
shown
furthermor
hemopexin
immunoprecipit
serum
mab
fig
c
sera
sever
group
patient
tabl
assess
lrg
employ
indirect
elisa
describ
microbi
infect
repres
two
group
fig
cyt
c
concentr
report
found
normal
serum
inhibit
lrg
detect
elisa
shown
competit
experi
increas
concentr
solubl
cyt
c
inhibit
bind
lrg
present
serum
platebound
cyt
c
lrg
serum
protein
adsorb
cyt
caffigel
b
cyt
cbind
serum
protein
bind
specif
nativ
cyt
c
recogn
mab
see
text
protein
sera
pool
control
subject
tss
patient
ml
total
adsorb
hors
cyt
caffigel
elut
visual
sdspage
identifi
mass
spectrometri
see
text
hemopexin
bind
expos
heme
denatur
cyt
c
plasmin
like
adsorb
affin
column
due
affin
lysin
residu
patient
tss
bacterium
infect
hiv
viru
infect
two
group
patient
previous
assess
serum
lrg
patient
inflammatori
arthriti
neurolog
disord
includ
pd
control
subject
span
age
individu
patient
group
male
femal
includ
group
examin
averag
level
lrg
tss
patient
significantli
greater
level
control
subject
sera
test
assay
p
test
p
b
bonferonni
post
test
anova
shown
fig
result
consist
publish
assess
serum
lrg
qualit
mean
sever
group
patient
variou
bacteri
infect
bini
et
al
anoth
elisa
serum
lrg
hiv
patient
slightli
higher
level
uninfect
control
subject
p
test
significantli
differ
control
group
p
n
bonferonni
post
test
anova
serum
lrg
patient
inflammatori
arthriti
fig
averag
compar
control
subject
test
assay
statist
distinct
p
test
p
n
bonferonni
post
test
anova
serum
lrg
level
neurolog
patient
averag
compar
control
subject
test
assay
p
test
p
n
bonferonni
post
test
anova
fig
one
pd
patient
high
lrg
level
includ
data
set
known
whether
outlier
may
result
microbi
infect
concentr
lrg
control
subject
averag
across
test
standard
error
standard
deviat
median
concentr
lrg
percentil
percentil
base
yield
lrg
purif
pool
human
serum
concentr
lrg
previous
estim
takahashi
et
al
lower
amount
quantifi
earlier
studi
like
due
loss
protein
purif
process
slight
variat
averag
lrg
level
within
pool
control
subject
among
experi
present
studi
may
due
differ
prepar
lrg
employ
standard
experi
lrg
crp
produc
liver
respons
inflamm
acutephas
protein
possibl
measur
biomark
could
redund
therefor
also
quantifi
crp
sever
patient
group
employ
commerci
sandwich
elisa
crp
determin
crp
lrg
provid
independ
measur
shown
fig
two
tss
patient
highest
level
serum
lrg
low
moder
level
crp
note
median
level
crp
healthi
individu
mgml
ridker
two
tss
patient
extrem
high
crp
level
slightli
elev
level
lrg
two
tss
patient
extrem
high
lrg
level
normal
level
crp
patient
averag
level
lrg
crp
tss
patient
two
biomark
correl
r
p
inflammatori
arthriti
patient
statist
differ
control
subject
basi
serum
lrg
often
median
level
crp
correl
quantiti
lrg
crp
sera
r
p
hivinfect
group
patient
also
correl
r
p
among
patient
test
crp
correl
serum
lrg
crp
r
p
report
indirect
elisa
human
lrg
describ
employ
lrg
ligand
cyt
c
captur
agent
use
assay
quantif
lrg
human
sera
also
assess
assay
sensit
least
ngml
requir
normal
serum
contain
approxim
lrg
dilut
test
sera
contain
higher
concentr
lrg
may
requir
dilut
due
extrem
low
concentr
cyt
c
may
present
serum
ngml
rel
amount
lrg
quantif
lrg
assay
inhibit
endogen
cyt
c
employ
lrgspecif
mab
immunoprecipit
lrg
along
bound
cyt
c
could
detect
cyt
c
associ
lrg
human
sera
use
western
blot
sensit
picogram
quantiti
fig
competit
elisa
solubl
cyt
cmediat
inhibit
lrg
captur
began
observ
concentr
higher
upper
limit
cyt
c
estim
present
normal
serum
howev
complet
inhibit
observ
higher
concentr
indic
caution
interpret
result
elisa
describ
herein
requir
patient
high
serum
cyt
c
level
lrg
shown
inhibit
cyt
c
detect
least
one
sandwich
elisa
format
cum
et
al
lrg
cyt
c
level
measur
optim
clinic
assess
two
biomark
lrg
found
elev
certain
patient
group
other
patient
inflammatori
arthriti
neurolog
condit
includ
pd
normal
level
lrg
contrast
least
half
patient
tss
elev
level
lrg
anoth
studi
report
elsewher
assay
identifi
elev
serum
lrg
level
number
patient
ovarian
cancer
dr
ami
skubitz
univers
minnesota
person
commun
thu
find
support
sever
group
employ
qualit
approach
twodimension
gel
electrophoresi
western
blot
assess
lrg
level
sera
microbiallyinfect
individu
patient
sever
type
cancer
bini
et
al
chen
et
al
jiang
et
al
kakisaka
et
al
kawakami
et
al
okano
et
al
distinct
lrg
crp
level
sever
patient
group
suggest
two
biomark
serv
distinct
indic
diseas
even
though
protein
secret
liver
crp
lrg
produc
respons
inflamm
classifi
acutephas
protein
low
level
lrg
observ
inflammatori
arthriti
patient
frequent
high
level
crp
two
tss
patient
highest
serum
level
lrg
averag
moder
level
crp
two
patient
extrem
high
crp
level
low
serum
lrg
level
statist
correl
serum
lrg
crp
patient
group
examin
find
consist
kakisaka
et
al
observ
normal
level
serum
lrg
low
level
crp
pancreat
cancer
patient
relev
elev
lrg
certain
patient
group
understood
function
protein
unknown
previou
find
lrg
bind
cyt
c
cum
et
al
lrg
compet
bind
cyt
c
thompson
et
al
suggest
lrg
may
antiapoptot
factor
allow
surviv
cell
respons
stress
signal
support
hypothesi
lrg
gene
upregul
lung
muscl
cell
within
h
follow
exposur
poison
ncbi
gd
gd
downregul
h
lrg
mrna
also
invers
express
mani
tissu
mous
includ
liver
suggest
oppos
function
ncbi
gd
regard
cancer
lrg
mrna
express
found
elev
ovarian
cancer
cell
line
examin
consist
increas
serum
lrg
least
half
ovarian
cancer
patient
ncbi
gd
remain
determin
whether
lrg
sera
cancer
patient
produc
cancer
cell
tissu
liver
neutrophil
studi
pancreat
cancer
kakisaka
et
al
report
cultur
pancreat
cancer
cell
secret
lrg
lrg
also
observ
cell
infect
coronaviru
caus
sar
jiang
et
al
elev
lrg
serum
could
result
bodi
defens
cancer
could
reaction
liver
serum
factor
increas
respons
cancer
potenti
import
lrg
uniqu
biomark
highlight
studi
clinic
analysi
requir
determin
whether
quantif
serum
lrg
prognost
diagnost
valu
elev
serum
lrg
result
bodi
defens
cancer
high
lrg
level
may
bode
well
patient
howev
circul
lrg
level
associ
cancer
cell
surviv
poor
prognosi
may
indic
sandwich
elisa
describ
herein
use
tool
assess
question
futur
clinic
trial
